Insider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CFO Purchases 15,000 Shares of Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CFO Anna Mowry purchased 15,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Thursday, May 29th. The stock was acquired at an average cost of $0.77 per share, with a total value of $11,550.00. Following the acquisition, the chief financial officer now directly owns 83,000 shares of the company’s stock, valued at $63,910. The trade was a 22.06% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock opened at $0.77 on Thursday. The stock has a market cap of $97.75 million, a PE ratio of -1.38 and a beta of 1.43. The business’s fifty day moving average is $0.76 and its 200-day moving average is $1.37. Nautilus Biotechnology, Inc. has a 1 year low of $0.66 and a 1 year high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. Equities research analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of institutional investors have recently made changes to their positions in NAUT. SG Americas Securities LLC grew its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after buying an additional 9,904 shares in the last quarter. Palumbo Wealth Management LLC boosted its holdings in Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock valued at $48,000 after purchasing an additional 8,888 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Nautilus Biotechnology in the 4th quarter worth approximately $28,000. JPMorgan Chase & Co. boosted its holdings in shares of Nautilus Biotechnology by 309.9% in the 4th quarter. JPMorgan Chase & Co. now owns 145,937 shares of the company’s stock worth $245,000 after acquiring an additional 110,334 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Nautilus Biotechnology by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company’s stock worth $1,920,000 after acquiring an additional 7,000 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Guggenheim set a $2.50 price target on Nautilus Biotechnology in a research report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.